TEST FOR PARTICULATE CONTAMINATION:
SUB-VISIBLE PARTICLES

It is understood that sign-off covers the technical content of the draft and each party will adapt it as necessary to conform to the usual presentation of the pharmacopoeia in question; such adaptation includes stipulation of the particular pharmacopoeia’s reference materials and general chapters.

**European Pharmacopoeia**

Signature: 

Name: ARTIGES

Date: 21.05.01

**Japanese Pharmacopoeia**

Signature: S. Hasegawa

Name: Souichi Hasegawa

Date: 21.05.01

**United States Pharmacopeia**

Signature: 

Name: Roger William

Date: 21.05.01